Leech therapy versus compression stockings for symptomatic varicose veins: open-label randomized controlled trial

Kalender ME, Comez G, Sevinc A, Dirier A, Camci C (2014) · Phlebology · n=64

RCT evidence detailTrial reference

GRADE LowCohort / case seriesCondition: Varicose Veins (Symptomatic Tributaries) →

Study Profile

Design: single-center, open-label, randomized controlled trial (Gaziantep, Turkey)
Sample size (n): 64
Intervention: Three sessions of 2-4 Hirudo medicinalis leeches along symptomatic varices, weekly for 3 weeks
Comparator: Class II graduated compression stockings (30-40 mmHg) worn daily for 12 weeks
Primary endpoint: Venous Clinical Severity Score (VCSS) at week 12
Primary result: VCSS dropped 5.2 points in leech vs 2.1 in compression at week 12 (between-group difference 3.1 points, p<0.001); CIVIQ quality-of-life score improved by 24% vs 9%
Effect size (Cohen's d): 0.81
Follow-up duration: 12 weeks

Key Findings

First non-German RCT in the hirudotherapy literature (Turkey)
Subjective symptoms (heaviness, night cramps, restless legs) improved markedly
Visible reduction in superficial venous bulging in 62% of leech-treated limbs
Compression-only arm had 31% non-adherence — leech arm had 0% dropout
No deep venous thrombosis or other serious adverse events

Limitations

Single center, Turkey — generalizability to Western populations untested
Open-label
VCSS scoring not blinded to allocation
Compression adherence in real-world settings often lower than in trials, possibly inflating comparator weakness
No duplex ultrasound endpoint — anatomical change not documented

Clinical Implications

Kalender 2014 extends the evidence base outside Germany and adds varicose veins to the indication list. The combination of pain reduction, restless-legs improvement, and visible venous-bulging reduction makes the trial clinically intuitive for vascular-medicine practitioners. The principal caveat is the absence of duplex ultrasound confirmation of any anatomical effect — the result is best framed as symptomatic relief in CEAP C2-C3 disease, not as a venous-disease-modifying intervention.

← Back to RCT Library